Cantargia AB (“Cantargia”) presented new preclinical data at the 2020 Annual Meeting of the American Association for Cancer Research (AACR), June 22-24. The work was done in collaboration with Truly Labs and the data gave additional knowledge around the mechanisms and thereby relevance of adding the clinical stage antibody CAN04 to chemotherapy. CAN04 combined with different chemotherapy regimens resulted in additive or synergistic antitumor effects. View the full poster here or at www.cantargia.com.
Leave a reply